ARCTURUS THERAPEUTICS HLDGS's ticker is ARCT and the CUSIP is 03969T109. A total of 2 filers reported holding ARCTURUS THERAPEUTICS HLDGS in Q4 2023. The put-call ratio across all filers is - and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $4,965,541 | -8.1% | 194,346 | +3.2% | 0.00% | 0.0% |
| Q2 2023 | $5,401,362 | +152008.2% | 188,332 | +27.1% | 0.00% | +100.0% |
| Q1 2023 | $3,551 | +205.3% | 148,164 | +116.1% | 0.00% | – |
| Q4 2022 | $1,163 | -99.9% | 68,547 | -37.7% | 0.00% | -100.0% |
| Q3 2022 | $1,631,000 | -4.6% | 110,088 | +1.4% | 0.00% | 0.0% |
| Q2 2022 | $1,709,000 | -23.7% | 108,606 | -23.9% | 0.00% | 0.0% |
| Q1 2022 | $2,239,000 | -36.3% | 142,658 | +50.3% | 0.00% | 0.0% |
| Q4 2021 | $3,513,000 | -28.9% | 94,925 | -33.1% | 0.00% | -50.0% |
| Q3 2021 | $4,938,000 | +13.9% | 141,833 | +10.7% | 0.00% | +100.0% |
| Q2 2021 | $4,337,000 | +34.0% | 128,172 | -29.0% | 0.00% | 0.0% |
| Q1 2021 | $3,236,000 | -22.5% | 180,466 | -9.0% | 0.00% | 0.0% |
| Q4 2020 | $4,178,000 | +34.8% | 198,413 | +174.5% | 0.00% | 0.0% |
| Q3 2020 | $3,100,000 | +6.1% | 72,277 | +15.6% | 0.00% | 0.0% |
| Q2 2020 | $2,923,000 | – | 62,532 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| SEVEN EIGHT CAPITAL, LP | 46,819 | $2,031,000 | 0.47% |
| Orbimed Advisors | 1,206,886 | $49,844,000 | 0.47% |
| JACOB ASSET MANAGEMENT OF NEW YORK LLC | 25,000 | $1,033,000 | 0.40% |
| ARK Investment Management | 3,331,889 | $137,607,000 | 0.27% |
| FEDERATED HERMES, INC. | 3,203,000 | $132,284,000 | 0.26% |
| MGO ONE SEVEN LLC | 26,990 | $1,114,000 | 0.19% |
| Koss-Olinger Consulting, LLC | 20,000 | $826,000 | 0.14% |
| Jump Financial, LLC | 35,400 | $1,462,000 | 0.14% |
| Graham Capital Management, L.P. | 74,262 | $3,067,000 | 0.14% |
| New England Research & Management, Inc. | 6,005 | $248,000 | 0.14% |